IRLAB: Positive outcome from end-of-phase 2 meeting - Redeye

Redeye gives a short comment on the exciting news that the FDA and IRLAB have an aligned view on a future phase III program for Mesdopetam.

Länk till analysen i sin helhet: https://www.redeye.se/research/984066/irlab-positive-outcome-from-end-of-phase-2-meeting?utm_source=finwire&utm_medium=RSS